// App-Quantinova.ai

Filters

Biomarkers

No records found for your search

Conference Name

No records found for your search

Country

























Company

Search valid company name..

Conference Year













Drug











Disease

Medical Centers

Search valid medical center name..

Outcomes





Presenter

Search valid presenter name..

Principal Investigators

Search valid principal investigator name..

Phase










Patient Segments

Search valid patient segment..

Result



Sponsor

Search valid sponsor name..

Study ID

Search your valid Study ID..

Therapeutic Area
























28841 Abstracts

Increased heart rate is independently associated with worse survival in pediatric patients with dilated cardiomyopathy: a multicenter study from the pediatric cardiomyopathy registry

J. Rossano - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Impact of cardiovascular risk factors and disease on length of stay and mortality in patients with heart failure

H. Khawar - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Risks of cardiac implantable electronic device procedures performed with uninterrupted direct oral anticoagulant therapy

C. Allard - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Risk factors, predictors and outcomes of chronic total occlusions in ischaemic heart disease: big data from the UK ACALM registry

R. Potluri - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

The impact of patterns of long-term conditions on survival among patients with acute myocardial infarction: a national cohort study of 693,333 patients

M. Hall - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

N/A

N/A

Hemodynamic determinants of low gradient severe aortic stenosis: an in vitro study

J. Adda - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

External validation and improvement of EHMRG risk model using a population-based cohort of patients with heart failure

N. Sepehrvand - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Empagliflozin reduces heart failure irrespective of control of blood pressure, low density lipoprotein cholesterol and HbA1c

D. Fitchett - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

BI-10773

How important is the anticoagulant strategy in primary percutaneous coronary intervention? Insights from the ATLANTIC study

W.J. Cantor - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

Ticagrelor

Efficacy of evinacumab in homozygous familial hypercholesterolemia patients with null or non-null LDL-receptor mutations and on various background therapies

D. Gaudet - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Genetic Disorder

N/A

evinacumab

Long-term outcome of total arterial myocardial revascularization versus conventional coronary artery by-pass in diabetic and non diabetic patients: a propensity-match analysis

C. Muneretto - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

N/A

Empagliflozin reduces mortality in analyses adjusted for control of blood pressure, low density lipoprotein cholesterol and HbA1c over time

B. Zinman - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

N/A

N/A

BI-10773

Effect of extended-duration thromboprophylaxis on venous thromboembolism and major bleeding among acutely ill hospitalized medical patients: a bivariate analysis

G. Chi - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Long term follow-up of the trial of routine angioplasty and stenting after fibrinolysis to enhance reperfusion in acute myocardial infarction (transfer AMI)

L.M. Morrison - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Transradial bilateral or single access in iliac artery percutaneous interventions: early and late results

D. Petkoska - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Invasive treatment of the critical hand ischaemia: long term results

Z. Ruzsa - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Effects of empagliflozin on cardiac and vascular hemodynamic markers by subgroups of age, sex and hypertension in patients with T2DM and high CV risk: EMPA-reg outcome

R.J. Chilton - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

N/A

BI-10773

Anticoagulant use and associated outcomes in patients with atrial fibrillation and advanced kidney disease

P. Noseworthy - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Central Nervous System (CNS)

N/A

N/A

Apabetalone (RVX-208) impacts key biomarkers and pathways associated with cardiovascular disease in patients with severe renal impairment

N. Wong - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Nephrology

N/A

RVX-208

Education is the main predictor for successful employment in adults with congenital heart disease worldwide

M.A. Sluman - European Society of Cardiology (ESC) , 2017

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

N/A

N/A

Copyright © 2026. QuantiNova All rights reserved